PerkinElmer
check quantity

LANCE Ultra Europium-anti-unmodified Histone H3 Lysine 9/Lysine 27 (H3K9/K27) Antibody, 10 µg

Europium-labeled monoclonal antibody recognizing human Histone H3 that is unmodified at lysine 9 and lysine 27 (H3K9/K27). For use in LANCE® Ultra epigenetic writer and eraser assays.

You successfully added item(s) to your cart

Part Number
Unit Size
List Price
Your Price
Quantity
TRF0411-D
10 µg
3484.00 USD
more
TRF0411-M
100 µg
8700.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

The LANCE® Ultra Europium-anti-unmodified Histone H3 Lysine 9/Lysine 27 (H3K9/K27) antibody was used for the development and optimization of epigenetic writer and eraser assays.

Formats:

  • 10 µg = 1,500 assay points (384-well assay format)
  • 100 µg = 15,000 assay points (384-well format)

Proven, cost-efficient LANCE Ultra reagents can be used to quantitate peptide modifications, detecting specific meythylation and acetylation states. No wash, homogenous LANCE Ultra reagents are HTS friendly - design your own epigenetics screening strategy for greatest efficiency.


Epigenetic enzymatic assays are optimized using a biotinylated histone H3-derived peptide as substrate. The modified peptide is captured by the Eu-labeled antibody (Ab) and ULight-Streptavidin (SA) which bring the Eu donor and ULight acceptor dye molecules into close proximity. Upon irradiation at 320 or 340 nm, the energy from the Eu donor is transferred to the ULight acceptor dye which, in turn, generates light at 665 nm. The intensity of the light emission is proportional to the level of biotinylated substrate modification.

Specifications

Antibody Conjugates Anti-H3K9/H3K27
Automation Compatible Yes
Detection Method Time-Resolved Fluorescence (TRF), TR-FRET
Experimental Type In vitro
Fluorophore Eu-W1024
Molecular Modification Acetylation,Methylation
Product Brand Name LANCE Ultra
Shipping Condition Dry Ice
Unit Size 10 µg
Resources, Events & More
  • All

Brochure

EPIGENETICS DRUG DISCOVERY SOLUTIONS

Epigenetics, the study of changes in gene expression, is a rapidly growing field which, presents a significant opportunity for drug discovery. As the understanding of the role, of epigenetic changes in various disease states advances, the need for high quality, reagents that can rapidly identify and optimize therapeutic molecules that target these, enzymes is increasing.

PDF 666 KB

Technical Note

LANCE Ultra HDAC1 Histone H3-Lysine 9 Deacetylase Assay

In this technical note, we present the optimization of an HDAC1, enzymatic assay using as substrate a biotinylated histone H3-derived, peptide acetylated at lysine 9. The deacetylated peptide product is, captured by the Eu-labeled antibody (Eu-Ab) and ULight-Streptavidin, (ULight-SA), which bring the Eu donor and ULight acceptor dye, molecules into close proximity. Upon irradiation at 320 or 340 nm, the energy from the Eu donor is transferred to the ULight acceptor, dye which, in turn, generates light at 665 nm. The intensity of the, light emission is proportional to the deacetylation activity of the, HDAC1 enzyme.

PDF 678 KB
LANCE Ultra JMJD1A Histone H3-Lysine 9 Demethylase Assay

LANCE Ultra time-resolved fluorescence resonance energy transfer, (TR-FRET) assays use a proprietary europium chelate donor dye, W1024 (Eu), together with ULight™, a small molecular weight, acceptor dye with a red-shifted fluorescent emission.

PDF 734 KB